ALZAMEND NEURO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ALZAMEND NEURO, INC. (ALZN) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $6.88 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-10
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-07-31 was $6.88M, a 311.48% increase year-over-year.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-07-31 was $1.67M, a 104.45% increase year-over-year.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-07-31 was $817.90K.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-07-31 was -$3.45M.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2026 was -$3.24M, a 190.63% decline from fiscal 2025.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $3.57M.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$4.76M.
- ALZAMEND NEURO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$8.92M, a 173.53% decline from fiscal 2022.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-07-31 | $6.88M 10-Q · filed 2026-09-10 | |||
| 2026-04-30 | -$3.24M 10-K · filed 2026-07-22 | |||
| 2026-01-31 | -$1.24M 10-Q · filed 2026-03-11 | |||
| 2025-10-31 | $500.77K 10-Q · filed 2025-12-09 | |||
| 2025-07-31 | $1.67M 10-Q · filed 2026-09-10 | |||
| 2025-04-30 | $3.57M 10-K · filed 2026-07-22 | |||
| 2025-01-31 | $2.98M 10-Q · filed 2026-03-11 | |||
| 2024-10-31 | $3.72M 10-Q · filed 2025-12-09 | |||
| 2024-07-31 | $817.90K 10-Q · filed 2025-09-10 | |||
| 2024-04-30 | -$4.76M 10-K · filed 2025-07-22 | |||
| 2024-01-31 | -$4.86M 10-Q · filed 2025-03-10 | |||
| 2023-10-31 | -$4.94M 10-Q · filed 2024-12-11 | |||
| 2023-07-31 | -$3.45M 10-Q · filed 2024-09-11 | |||
| 2023-04-30 | -$8.92M 10-K · filed 2024-07-30 | |||
| 2023-01-31 | -$6.69M 10-Q · filed 2024-03-25 | |||
| 2022-10-31 | -$4.88M 10-Q · filed 2023-12-15 | |||
| 2022-07-31 | -$2.54M 10-Q · filed 2023-09-13 | |||
| 2022-04-30 | $12.13M 10-K · filed 2023-07-27 | |||
| 2022-01-31 | $9.86M 10-Q · filed 2023-03-15 | |||
| 2021-10-31 | $11.64M 10-Q · filed 2022-12-12 | |||
| 2021-07-31 | $13.69M 10-Q · filed 2022-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |